Borel Florie, van Logtenstein Richard, Koornneef Annemart, Maczuga Piotr, Ritsema Tita, Petry Harald, van Deventer Sander Jh, Jansen Peter Lm, Konstantinova Pavlina
Department of Research and Development, Amsterdam Molecular Therapeutics, Amsterdam, The Netherlands.
J RNAi Gene Silencing. 2011;7:434-42. Epub 2011 Jun 17.
ABC transporters export clinically-relevant drugs and their over-expression causes multidrug resistance. In order to knock-down ABC transporters, ABCC1 and ABCC2, 13 shRNAs were developed. Four shRNA candidates were tested in vivo using self-complementary adeno-associated virus serotype 8. A strong, specific knock-down of Abbc2 was observed in mice liver, but at the cost of toxicity caused by oversaturation of the RNAi machinery due to high shRNA expression. Subsequent generation of artificial miRNAs showed better efficacy profile. These results demonstrate the feasibility of knocking down Abbc2 via AAV-delivered shRNAs to the liver, and encourage the use of miRNA in further therapeutics development.
ABC转运蛋白可输出具有临床相关性的药物,其过表达会导致多药耐药性。为了敲低ABC转运蛋白ABCC1和ABCC2,开发了13种短发夹RNA(shRNA)。使用自我互补腺相关病毒血清型8在体内测试了4种shRNA候选物。在小鼠肝脏中观察到Abbc2的强烈、特异性敲低,但代价是由于高shRNA表达导致RNAi机制过度饱和而产生毒性。随后生成的人工微小RNA(miRNA)显示出更好的疗效。这些结果证明了通过腺相关病毒将shRNA递送至肝脏来敲低Abbc2的可行性,并鼓励在进一步治疗开发中使用miRNA。